Trial Profile
A Phase 2, Single-Arm, Open-label, Study of RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Nov 2019
Price :
$35
*
At a glance
- Drugs Nibrozetone (Primary) ; Cisplatin; Gemcitabine
- Indications Adenocarcinoma; Cholangiocarcinoma
- Focus Therapeutic Use
- Acronyms EPIC
- Sponsors EpicentRx
- 13 Nov 2019 Status changed from active, no longer recruiting to discontinued.
- 04 Jun 2018 Planned End Date changed from 1 Aug 2017 to 1 Dec 2018.
- 04 Jun 2018 Planned primary completion date changed from 1 Aug 2017 to 1 Jun 2018.